RNA-targeted small molecule discovery has generated considerable interest of late, given the recent approval of a molecule in this class for spinal muscular atrophy. In this talk, Dr. Santosh Kulkarni from Syngene shares insights into current drug discovery approaches and emerging areas of RNA targeting, such as RIBOTACs, Epitranscriptomics and target validation methodologies.
To know more, write to 👉 bdc@syngeneintl.com. or
Visit us at 👉 www.syngeneintl.com
